Research Team Led by Liu Dongyang From Peking University Third Hospital and Collaborators Publishes Findings, Providing a Theoretical Foundation for Combination Therapy in Type 2 Diabetes

Author: Liu Huan

https://www.puh3.net.cn/info/1971/173461.htm

On April 21, the team led by Researcher Liu Dongyang from the Drug Clinical Trial Institution of Peking University Third Hospital, in collaboration with the team led by Dr. Chen Li, published a research article titled "A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial" in Nature Communications.

Using descriptive statistics and an innovative pharmacodynamic mathematical model, the research team systematically evaluated the effects of combined dorzagliatin and empagliflozin therapy. The study deeply revealed the respective contributions of the two drugs to improving β-cell function and insulin sensitivity at different time phases when used in combination, providing a solid theoretical basis for their combined clinical application.

Liu Dongyang and Chen Li are co-corresponding authors. Liu Huan, a master's student at Peking University Third Hospital, and postdoctoral fellow Zhang Yuanhui are co-first authors.

Screenshot of the Paper

Original Link: https://doi.org/10.1038/s41467-026-71798-x